All In Biotech

Drug Trial Radar · NCT03156153

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder:a Randomized Double-blind Placebo-controlled Trial

Last checked: Nov 20, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

May 24, 2017

Primary completion

Jul 8, 2019

Study completion Jul 10, 2019

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Shanghai Jiao Tong University School of Medicine
First posted
May 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.

Conditions

  • Autism Spectrum Disorder

Interventions

  • BumetanideDrug

    bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

  • PlaceboDrug

    placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Childhood Autism Rating Scale(CARS)Time frame: Day 0 and Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinhua Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.